Scientists said on Wednesday a new drug tested on monkeys provided an astonishingly effective shield against an animal version of the AIDS virus, a major gain in the quest for an HIV vaccine.
Macaque monkeys given the drug were able to fend off high repeated doses of the simian version of the human immunodeficiency virus (HIV), they reported in the journal Nature.
"We... show a way to achieve long-lived, effective, vaccine-like protection from HIV 1," the main group of viral strains in humans, said study leader Michael Farzan, a professor at the Scripps Research Institute in Florida.
The mimics latch on to the virus, tricking it into prematurely launching the docking procedure. The virus can only execute the procedure once, rendering it unable to attach to CD4 cells thereafter.
The paper reported on a 40-week experiment which showed that inoculated animals thrived even after being injected with four times the dose needed to infect macaques in a "control" group.
The search for a vaccine has been one of the most frustrating chapters of the AIDS saga. Traditional antibody-based vaccine candidates have failed to put up more than a partial shield, partly because of mutations in the stealthy virus.
Lab-dish tests have found that the drug also works on human HIV, which is very close to the simian version of the virus.
"Unlike antibodies, which fail to neutralise a large fraction of HIV-1 strains, our protein has been effective against all strains tested, raising the possibility it could offer an effective HIV vaccine alternative," said Farzan.
Since 1981, about 78 million people have been infected by HIV, which destroys immune cells and leaves the body exposed to tuberculosis, pneumonia and other opportunistic diseases. Thirty-nine million have died, according to UN estimates.
Treatment burden
Treatment is lifelong, carries side effects and for many health systems, the drugs bill is spiralling, said Anthony Fauci, head of the US National Institute of Allergy and Infectious Diseases (NIH), whose parent organisation funded the research.
"This innovative research marks an important step toward our goal of putting HIV into sustained remission in chronically-infected people," Fauci said in a press release.
The approach behind eCD4-Ig is based on the idea that two is better than one. Separately, the two mimics are not effective, but together they are.
They are delivered into the body inside a harmless adenovirus that is used extensively in medical research.
Once injected into muscle tissue, the virus uses cells to crank out the protective protein, in quantities that could last for years.
Canada-Based Terrorist Lakhbir Landa's Key Aide Arrested German Man, 60, Seventh Person To Be Likely "Cured" Of HIV: Doctors India Sends First Tranche Of $2.5 Million For Palestinian Refugees Over 300 Indian Students Return Home As 105 Bangladeshis Killed In Protests "Jindal Group Executive Showed Porn, Groped Me On Flight": Woman To NDTV Bangladesh Imposes Curfew, Deploys Military As 105 Die In Protests 1,100 Flights Cancelled In US As Microsoft Outage Disrupts Operations Elon Musk Congratulates PM Modi On Becoming Most Followed Leader On X With Shadow Cabinet, Naveen Patnaik Makes His Intentions Clear Track Latest News Live on NDTV.com and get news updates from India and around the world.